Hospital Days Fundraising Priority

Banner with Hospital Days Logo and $50,000 Matching Grant

The 2023 Hospital Days beneficiary is NLH's Hematology-Oncology Infusion Services. Funds raised will help improve and enhance the infusion patient experience. 

Support Infusion Services

Make a gift online by credit card through our secure server. If you would like your gift to be recognized towards our Hospital Days fundraising beneficiary, our Infusion Services, please be sure to choose “Infusion Services” in the drop-down on our online form. Thank you!

Donate now 

Printable Donation Form    

$50,000 Matching Challenge 

The Jack and Dorothy Byrne Foundation (Byrne Foundation) has committed to match donations to New London Hospital’s (NLH) Hospital Days dollar-for-dollar, up to $50,000, to inspire the community to support Hematology-Oncology Infusion Services, the beneficiary of Hospital Days gifts and proceeds. 

This matching gift challenge is part of NLH’s Hospital Days fundraising initiative to raise funds that will help improve and enhance the infusion patient experience. Gifts will impact every area of the infusion patient experience, from esthetic updates to the infusion suite to items that will provide warmth and comfort to patients during their treatments. Learn more about the challenge

What is Infusion Therapy? 

New London Hospital’s Infusion Services provides intravenous medications that are administered by our team of highly-skilled and compassionate registered nurses. We are honored to provide thorough medical care to members of our community with cancer, blood disorders and other non-cancer-related conditions.

We provide infusions for the treatment of:

  • Arthritis
  • Crohn’s disease
  • Cancer
  • Hydration and Electrolyte
  • Replacement
  • Multiple sclerosis
  • Osteoporosis
  • Among many other conditions

Infusion Services by the Numbers* 

  • Total visits: 2,164
  • Age range of patients: 17-98 years old
  • Appointment length: 20 minutes up to 6.5 hours
  • Percentage of visits related to cancer treatments: 33.53%

*January 2022-May 2023